IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guy A. Rouleau et al.

Serial No.: 10/664,603

Filed: September 17, 2003

For: LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME TO ASSESS, DIAGNOSE, PROGNOSE OR TREAT EPILEPSY Group Art Unit: 1639

Examiner: Sue Xu Liu

Atty. Dkt. No.: GOUD:023USD1

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: October 4, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Denosit Account No.: 50-1212/GOUD:023USD1.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Michael R. Krawzsenek Reg. No. 51,898 Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: October 4, 2006

								Page 1 of 1	
Form P	TO-144	9 (modified)	Atty. Doeket No.			Serial No.			
				GOUD:023USD1			10/664,603		
List of Patents and Publications for Applicant's				Applicant					
				Guy A. Rouleau et	al.				
INF	ORMATIC	ON DISCLOSURE STA	TEMENT						
(Use several sheets if necessary)				Filing Date:			Group:		
		Documents	September 17, 2003 1639						
U.		Documents Page I		Foreign Patent Doeuments See Page 1		Other Art See Page 1			
	See r	age I	3	ce Page 1	٠.		See Page	1	
		ı	J.S. Pate	nt Document	s				
Exam.	Ref.	Document	Date	Name		Class	Sub	Filing Date	
Init.	Des.	Number	50.0			0,000	Class	of App.	
	A2	6,110,672	08/29/00	Mandel et al.			6	11/02/95	
		Fo	reign Pa	tent Docume	nts				
Exam. Init.	Ref. Des.	Document Number	Date	Country		Language			
	B2	WO 96/14077	05/17/96	WIPO		English			
)then	A = (l= = l::dl==	Author	Title Dete De		D		-4- \	
		Art (Including	Autnor,	Title, Date Pe	ertin	ent Pa	ages, I	Etc.)	
Exam. Init.	Ref. Des.	Citation							
	C75	"Table of Contents," Annals of the New York Academy of Sciences, 868, 1999.							
	C76	Clare et al., "Cloning and Functional Analysis of the Type III Na+ Channel from Human Brain," Annals of the New York Academy of Sciences, 868:80-83, 1999.							
	C77	GenBank Accession No. AF035685.							
	C78	NCBI Accession No. X03638.							
	C79	Noda et al., "Existence of distinct sodium channel messenger RNAs in rat brain," Nature, 320: 188-192, 1986.							
	C80	Rudinger, "Characteristics of the amino acids as components of a peptide hormone sequence," In: Pentide Hormones (ed. J.A. Parsons) I Injuryativ Pack Press, Baltimore, pp. 1-7, 1976							

25703819.1

C81

99:1714-1720, 1997.

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Wang et al., "Pharmacological Targeting of Long QT Mutant Sodium Channels," J. Clin. Invest.,